All In Biotech

NDA 019763 · Baxter Hlthcare

Ifex/Mesnex Kit

Ifosfamide, Mesna · Injection · Alkylating Drug

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Aug 14, 1987

Approved uses

1

Original approval plus efficacy supplements

Registered trials

517

121 Phase 3, 52 recruiting

FAERS reports

21,791

21,243 serious, 4,473 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY • Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle [see Warnings and Precautions (5.1) ]. • Encephalopathy can be severe and may result in death. Monitor for CNS toxicity and discontinue treatment for encephalopathy [see Warnings and Precautions (5.2) ]. • Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna [see Warnings and Precautions (5.3) ]. WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY See full prescribing information for complete boxed warning . • Myelosuppression can be severe and lead to fatal infections ( 5.1 ) • Encephalopathy can be severe and may result in death ( 5.2 ) • Nephrotoxicity can be...

What it is approved for

From the label in effect Oct 7, 2026.

Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. Ifosfamide for Injection is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. ( 1 )

Mechanism: Ifosfamide is a prodrug that requires metabolic activation by hepatic cytochrome P450 isoenzymes to exert its cytotoxic activity. Activation occurs by hydroxylation at the ring carbon atom forming the unstable intermediate 4‑hydroxyifosfamide and its ring-opened aldo tautomer, which decomposes to yield the cytotoxic and urotoxic compound acrolein and an alkylating isophosphoramide mustard isophosphoramide mustard. The exact mechanism of action of ifosfamide has not been determined, but its cytotoxic action is primarily through DNA crosslinks caused by alkylation by the isophosphoramide...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 14, 1987 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • IFEX/MESNEX KIT · IFOSFAMIDE 1GM/VIAL; MESNA 100MG/ML · INJECTABLE, INJECTION · Discontinued
  • IFEX · IFOSFAMIDE 1GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • IFEX/MESNEX KIT · IFOSFAMIDE 3GM/VIAL; MESNA 100MG/ML · INJECTABLE, INJECTION · Discontinued
  • IFEX · IFOSFAMIDE 3GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ifosfamide" as an intervention, any sponsor and status, largest first.

All 517 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,896
  • febrile neutropenia2,740
  • disease progression2,145
  • neutropenia1,931
  • drug ineffective1,626
  • thrombocytopenia1,578
  • anaemia1,277
  • pyrexia1,028
  • product use in unapproved indication964
  • sepsis888
  • pancytopenia836
  • infection822

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004208
2005200
2006145
2007219
2008236
2009249
2010284
2011580
2012686
2013514
2014410
2015893
2016843
20171,169
20181,263
20191,448
20201,833
20211,630
20222,092
20232,275
20241,896
20251,561
20261,155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01).

  • Current · updated Nov 18, 2026

    Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01).

  • Current · updated Nov 18, 2026

    IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01).

  • Current · updated Nov 18, 2026

    Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Ifex* (Ifosfamide*) · HCPCS J9208

2024 spending

$46K

Beneficiaries

67

446 claims

Per beneficiary

$689

2024 ASP limit $25.96 per unit

View as table
YearSpending
2020$119,274
2021$124,012
2022$77,067
2023$58,705
2024$46,148

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,624 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Ifex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.